the EMA (European Medicines Agency) approved the long-awaited treatment after initially blocking it in July, reports RTBF ...
A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...
Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...
EMA's human medicines committee issued positive recommendations for multiple drugs, including Merck's Keytruda and InflaRx's ...
The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November ...
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback